Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8661)
All Articles published online
|
Dec 7, 2012 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Wang Y, Shen L, Xu N, Wang JW, Jiao SC, Liu ZY, Xu JM. |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i45/6635.htm |
| Number | Citing Articles |
| 1 |
Beata Franczyk, Jacek Rysz, Anna Gluba-Brzózka. Pharmacogenetics of Drugs Used in the Treatment of Cancers. Genes 2022; 13(2): 311 doi: 10.3390/genes13020311
|
| 2 |
Darius Wlochowitz, Martin Haubrock, Jetcy Arackal, Annalen Bleckmann, Alexander Wolff, Tim Beißbarth, Edgar Wingender, Mehmet Gültas. Computational Identification of Key Regulators in Two Different Colorectal Cancer Cell Lines. Frontiers in Genetics 2016; 7 doi: 10.3389/fgene.2016.00042
|
| 3 |
Femke M. de Man, Andrew K. L. Goey, Ron H. N. van Schaik, Ron H. J. Mathijssen, Sander Bins. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clinical Pharmacokinetics 2018; 57(10): 1229 doi: 10.1007/s40262-018-0644-7
|
| 4 |
Ammara Siddique, Samra Bashir, Mateen Abbas. Therapeutic Approaches in Cancer Treatment. Cancer Treatment and Research 2023; 185: 141 doi: 10.1007/978-3-031-27156-4_9
|
| 5 |
Satoru Iwasa, Kei Muro, Satoshi Morita, Young Suk Park, Masato Nakamura, Masahito Kotaka, Tomohiro Nishina, Hiroshi Matsuoka, Joong Bae Ahn, Keun‐Wook Lee, Yong Sang Hong, Sae Won Han, Sang‐Hee Cho, Dong‐Sheng Zhang, Wei‐Jia Fang, Li Bai, Xiang‐Lin Yuan, Ying Yuan, Yasuhide Yamada, Junichi Sakamoto, Tae Won Kim. Impact ofUGT1A1genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer. Cancer Science 2021; 112(11): 4669 doi: 10.1111/cas.15092
|
| 6 |
Fei-fei Han, Chang-long Guo, Dan Yu, Jin Zhu, Li-li Gong, Guang-run Li, Ya-li Lv, He Liu, Guang-yu An, Li-hong Liu. Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemotherapy and Pharmacology 2014; 73(4): 779 doi: 10.1007/s00280-014-2405-0
|
| 7 |
Qian-Qian Yu, Hong Qiu, Ming-Sheng Zhang, Guang-Yuan Hu, Bo Liu, Liu Huang, Xin Liao, Qian-Xia Li, Zhi-Huan Li, Xiang-Lin Yuan. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy. World Journal of Gastroenterology 2016; 22(16): 4250-4258 doi: 10.3748/wjg.v22.i16.4250
|
| 8 |
Zhaoqian Liu, Chenxue Mao, Xiangping Li, Jiye Yin. Pharmacogenomics in Precision Medicine. 2020; : 39 doi: 10.1007/978-981-15-3895-7_3
|
| 9 |
Dimitra-Ioanna Lampropoulou, Gerasimos Aravantinos, Hector Katifelis, Foivos Lazaris, Konstantinos Laschos, Theodosios Theodosopoulos, Christos Papadimitriou, Maria Gazouli. Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer. Cancer Biomarkers 2019; 25(2): 213 doi: 10.3233/CBM-182383
|
| 10 |
Hideki Matsuoka, Ryusuke Murakami, Kaoru Abiko, Ken Yamaguchi, Akihito Horie, Junzo Hamanishi, Tsukasa Baba, Masaki Mandai. UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07225-1
|
| 11 |
Chalirmporn Atasilp, Mohitosh Biswas, Pimonpan Jinda, Nutthan Nuntharadthanaphong, Jiratha Rachanakul, Yaowaluck Hongkaew, Natchaya Vanwong, Surasak Saokaew, Chonlaphat Sukasem. Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis. Clinical and Translational Science 2022; 15(7): 1613 doi: 10.1111/cts.13277
|
| 12 |
Jai N Patel, Charles S Fuchs, Kouros Owzar, Zihua Chen, Howard L McLeod. Gastric Cancer Pharmacogenetics: Progress or Old Tripe?. Pharmacogenomics 2013; 14(9): 1053 doi: 10.2217/pgs.13.88
|
| 13 |
Yingqi Zhang, Seumsack Dennis Somtakoune, Christina Cheung, Mario Listiawan, Xiaodong Feng. Therapeutic Application of Pharmacogenomics in Oncology. The AAPS Journal 2016; 18(4): 819 doi: 10.1208/s12248-016-9926-x
|
| 14 |
Lei Cheng, Ming Li, Jing Hu, Wei Ren, Li Xie, Zhan-Peng Sun, Bao-Rui Liu, Gen-Xing Xu, Xiao-Liang Dong, Xiao-Ping Qian. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer Chemotherapy and Pharmacology 2014; 73(3): 551 doi: 10.1007/s00280-014-2382-3
|
| 15 |
Lauren Walker, Vincent Yip, Munir Pirmohamed. Handbook of Pharmacogenomics and Stratified Medicine. 2014; : 405 doi: 10.1016/B978-0-12-386882-4.00020-7
|
| 16 |
Ron H. N. van Schaik. Pharmacogenomics in Clinical Practice. 2023; : 253 doi: 10.1007/978-3-031-45903-0_13
|
| 17 |
Zhe Wang, Xiaoyu Wang, Zhen Wang, Xiaoyu Fan, Mingrui Yan, Lili Jiang, Yangliu Xia, Jun Cao, Yong Liu. Prediction of Drug–Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation. European Journal of Drug Metabolism and Pharmacokinetics 2022; 47(3): 353 doi: 10.1007/s13318-021-00740-x
|
| 18 |
Yi-Jing Chen, Fei Hu, Chun-Yan Li, Jue-Min Fang, Li Chu, Xi Zhang, Qing Xu. The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. Biomarkers 2014; 19(1): 56 doi: 10.3109/1354750X.2013.867534
|
| 19 |
Chunlei Xu, Xushan Tang, Yanli Qu, Saifuding Keyoumu, Ning Zhou, Yong Tang. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology 2016; 78(1): 119 doi: 10.1007/s00280-016-3057-z
|
| 20 |
Bagher Larijani, Parisa Goodarzi, Motahareh Sheikh Hosseini, Solmaz M. Nejad, Sepideh Alavi-Moghadam, Masoumeh Sarvari, Mina Abedi, Maryam Arabi, Fakher Rahim, Najmeh Foroughi Heravani, Mahdieh Hadavandkhani, Moloud Payab. Genomics, Proteomics, and Metabolomics. Stem Cell Biology and Regenerative Medicine 2019; : 141 doi: 10.1007/978-3-030-27727-7_8
|
| 21 |
Anastasios Ntavatzikos, Aris Spathis, Paul Patapis, Nikolaos Machairas, George Peros, Stefanos Konstantoudakis, Danai Leventakou, Ioannis G Panayiotides, Petros Karakitsos, Anna Koumarianou. Integrating <i>TYMS</i>, <i>KRAS</i> and <i>BRAF</i> testing in patients with metastatic colorectal cancer. World Journal of Gastroenterology 2017; 23(32): 5913-5924 doi: 10.3748/wjg.v23.i32.5913
|
| 22 |
J M Campbell, M D Stephenson, E Bateman, M D J Peters, D M Keefe, J M Bowen. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. The Pharmacogenomics Journal 2017; 17(1): 21 doi: 10.1038/tpj.2016.58
|
| 23 |
Chalirmporn Atasilp, Pichai Chansriwong, Ekapob Sirachainan, Thanyanan Reungwetwattana, Apichaya Puangpetch, Santirhat Prommas, Suwannee Sirilerttrakul, Budsaba Rerkarmnuaychoke, Sansanee Wongwaisayawan, Chonlaphat Sukasem. Determination of irinotecan, SN‐38 and SN‐38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients. Journal of Clinical Laboratory Analysis 2018; 32(1) doi: 10.1002/jcla.22217
|
| 24 |
Grace Juyun Kim, Soo Youn Lee, Ji Hye Park, Brian Y. Ryu, Ju Han Kim. Role of Preemptive Genotyping in Preventing Serious Adverse Drug Events in South Korean Patients. Drug Safety 2017; 40(1): 65 doi: 10.1007/s40264-016-0454-5
|
| 25 |
Qian Zhu, Wanping Zhong, Xipei Wang, Liping Mai, Guodong He, Jiyan Chen, Lan Tang, Shuwen Liu, Weihua Lai, Shilong Zhong. Pharmacokinetic and Pharmacogenetic Factors Contributing to Platelet Function Recovery After Single Dose of Ticagrelor in Healthy Subjects. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00209
|
| 26 |
Xiaomu Kong, Ye Xu, Peng Gao, Yi Liu, Xuran Wang, Meimei Zhao, Yongwei Jiang, Hui Yang, Yongtong Cao, Liang Ma. Rapid detection of the irinotecan‐related UGT1A1*28 polymorphism by asymmetric PCR melting curve analysis using one fluorescent probe. Journal of Clinical Laboratory Analysis 2022; 36(8) doi: 10.1002/jcla.24578
|
| 27 |
Yuwei Yang, MengMeng Zhou, Mingjun Hu, Yanjie Cui, Qi Zhong, Ling Liang, Fen Huang. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan‐induced toxicity: A meta‐analysis. Asia-Pacific Journal of Clinical Oncology 2018; 14(5) doi: 10.1111/ajco.13028
|
| 28 |
XiaoXia Wei, JiaQin Cai, Hong Sun, Na Li, Chenxia Xu, Guifeng Zhang, Yuxia Sui, Jie Zhuang, Bin Zheng.
Cost–Effectiveness Analysis of
UGT1A1*6/*28
Genotyping for Preventing FOLFIRI-Induced Severe Neutropenia in Chinese Colorectal Cancer Patients
. Pharmacogenomics 2019; 20(4): 241 doi: 10.2217/pgs-2018-0138
|
| 29 |
Dan Liu, Jian Li, Jing Gao, Yanyan Li, Rui Yang, Lin Shen. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3406-2
|
| 30 |
Xu Ma, Sen Han, Ying Liu, Jing-Tao Liu, Jian Fang, Yan-Hua Zhang. Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations. Journal of Pharmacy and Pharmacology 2020; 72(11): 1528 doi: 10.1111/jphp.13333
|
| 31 |
Elena De Mattia, Erika Cecchin, Giuseppe Toffoli. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Drug Resistance Updates 2015; 20: 39 doi: 10.1016/j.drup.2015.05.003
|
| 32 |
Xue Zhang, Jia-Fu Yin, Jiao Zhang, Shu-Jia Kong, Hong-Yin Zhang, Xue-Mei Chen. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis. Cancer Chemotherapy and Pharmacology 2017; 80(1): 135 doi: 10.1007/s00280-017-3344-3
|
| 33 |
Alessia Bignucolo, Lucia Scarabel, Giuseppe Toffoli, Erika Cecchin, Elena De Mattia. Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers. Expert Review of Clinical Pharmacology 2022; 15(6): 689 doi: 10.1080/17512433.2022.2101447
|
| 34 |
Beibei Xu, Song Gao, Baojian Wu, Taijun Yin, Ming Hu. Absolute quantification of UGT1A1 in various tissues and cell lines using isotope label-free UPLC–MS/MS method determines its turnover number and correlates with its glucuronidation activities. Journal of Pharmaceutical and Biomedical Analysis 2014; 88: 180 doi: 10.1016/j.jpba.2013.08.024
|
| 35 |
Wenna Wang, Jing Huang, Yunxia Tao, Xiao Lyu, Lin Yang, Dawei Wu, Yantao Tian. Phase II and UGT1A1 Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatin as First-Line Therapy for Advanced Gastric Cancer. Chemotherapy 2016; 61(4): 197 doi: 10.1159/000442787
|
| 36 |
Juan Li, Bing Chen, Wen‐qi Xi, Wan Jia, Wei‐xia Zhang, Xiao‐lan Bian. Drug‐Drug Interactions and Disease Status Are Associated With Irinotecan‐Induced Hepatotoxicity: A Cross‐Sectional Study in Shanghai. The Journal of Clinical Pharmacology 2022; 62(9): 1160 doi: 10.1002/jcph.2059
|